David R. Epstein of Tempus AI, Inc. Sells 990 Shares

Tempus AI, Inc. (NASDAQ:TEM) recently reported that its Director, David R. Epstein, sold 990 shares of the company's stock on Monday, March 17th. The shares were sold at an average price of $46.83, resulting in a total transaction value of $46,361.70. After this sale, Epstein now holds 26,284 shares in Tempus AI, which have a current value of $1,230,879.72. This sale marks a 3.63% reduction in his overall ownership of the stock. The transaction was properly documented in a filing with the Securities and Exchange Commission (SEC), and the public can access this filing through the SEC's website.

Tempus AI Experiences Stock Movement

Following the announcement of the transaction, Tempus AI's stock saw an increase, trading up by $2.29 to reach $48.03 on Wednesday. The trading volume during this period was notable, with 11,624,616 shares changing hands, significantly higher than the average volume of 5,018,028 shares. Over the last year, Tempus AI's stock has experienced fluctuations, with a low of $22.89 and a high of $91.45. Financial ratios for the company indicate a quick ratio of 2.55 and a current ratio of 2.69, alongside a debt-to-equity ratio of 8.17. Additionally, the fifty-day moving average stands at $55.86, while the two-hundred day moving average is $51.48.

Recent Analyst Ratings for Tempus AI

Tempus AI has been the subject of various updates from analysts recently. Loop Capital revised their target price for Tempus AI from $57.00 to $52.00, maintaining a 'buy' rating in a report dated January 14th. William Blair reaffirmed a 'market perform' rating in a report published on February 25th. On March 4th, Piper Sandler lowered its price target for the stock from $70.00 to $55.00, assigning a 'neutral' rating. Conversely, Needham & Company LLC heightened their price target from $56.00 to $70.00 while retaining the 'buy' rating in a report on February 25th. Guggenheim also reaffirmed a 'buy' rating on the same date. The consensus rating for Tempus AI’s stock from analysts currently stands at 'Moderate Buy', with an average target price projected at $61.18.

Institutional Holdings in Tempus AI

Several hedge funds have adjusted their holdings in Tempus AI recently. GSA Capital Partners LLP acquired a new stake valued at approximately $306,000 during the third quarter. First Horizon Advisors Inc. also entered with a new investment valued at around $30,000. Moreover, The Manufacturers Life Insurance Company increased its position in Tempus AI by 10.2% during the third quarter, now owning 29,789 shares valued at $1,686,000 after purchasing an additional 2,765 shares. Captrust Financial Advisors invested in Tempus AI with a new stake worth approximately $2,726,000 in the same quarter. Additionally, NEA Management Company LLC boosted its holdings by 17.8%, now owning 5,385,979 shares valued at $304,846,000, making institutional investors and hedge funds own 24.22% of the stock.

About Tempus AI, Inc.

Tempus AI Inc is an innovative technology firm focused on advancing precision medicine through artificial intelligence, particularly in healthcare. The company aims to provide AI-driven solutions for personalized patient care, while simultaneously facilitating the exploration, development, and delivery of the best therapeutic options available.

Tempus, Epstein, Shares